Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

729588.pdf (4.51 MB)

Document type

Article

Version

Published version

Publication date

2022-12-09

Publication license

cc-by-nc-nd (c) Falato, Claudette et al., 2022
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/197288

Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1016/j.ctrv.2022.102496

Abstract

Traditionally, the classification of breast cancer relies on the expression of immunohistochemical (IHC) biomarkers readily available in clinical practice. Using highly standardized and reproducible assays across patient cohorts, intrinsic molecular subtypes of breast cancer - also called 'intrinsic subtypes' (IS) - have been identified based on the expression of 50 genes. Although IHC-based subgroups and IS moderately correlate to each other, they are not superimposable. In fact, non-luminal biology has been detected in a substantial proportion (5-20%) of hormone receptor-positive (HoR+) tumors, has prognostic value, and identifies reduced and increased sensitivity to endocrine therapy and chemotherapy, respectively. During tumor progression, a shift toward a non-luminal estrogen-independent and more aggressive phenotype has been demonstrated. Intrinsic genomic instability and cell plasticity, alone or combined with external constraints deriving from treatment selective pressure or interplay with the tumor microenvironment, may represent the determinants of such biological diversity between primary and metastatic disease, and during metastatic tumor evolution. In this review, we describe the distribution and the clinical behavior of IS as the disease progresses, focusing on HoR+/HER2-negative advanced breast cancer. In addition, we provide an overview of the ongoing clinical trials aiming to validate the predictive and prognostic value of IS towards their incorporation into routine care.

Subject

Càncer de mama, Marcadors bioquímics, Expressió gènica, Quimioteràpia del càncer, Tractament adjuvant del càncer, Metàstasi, Pronòstic mèdic

Subject (English)

Breast cancer, Biochemical markers, Gene expression, Cancer chemotherapy, Adjuvant treatment of cancer, Metastasis, Prognosis

Citation

Collections

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citation

FALATO, Claudette, et al. Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. Cancer Treatment Reviews. 2023. Vol. 112, num. 102496. ISSN 0305-7372. [consulted: 18 of August of 2026]. Available at: https://hdl.handle.net/2445/197288

Export metadata

JSON - METS

Share record